Companies / Crinetics Pharmaceuticals, Inc. / Activity
Activity — Crinetics Pharmaceuticals, Inc.
29 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Struthers Richard Scott CEO | Sell | Common Stock | $489.7K | -13K -3.09% | 413,563 0.39% of shares | medium |
| Mar 16, 2026 | Struthers Richard Scott CEO | Sell | Common Stock | $331.8K | -9K -2.12% | 404,778 0.38% of shares | medium |
| Mar 3, 2026 | Schilke Tobin Executive | Sell | Common Stock | $266.3K | -7K -7.91% | 78,121 0.07% of shares | medium |
| Mar 16, 2026 | Betz Stephen F. Executive | Sell | Common Stock | $236.4K | -6K -4.31% | 141,342 0.13% of shares | medium |
| Mar 16, 2026 | Knight Jeff E. Executive | Sell | Common Stock | $220.8K | -6K -4.88% | 115,979 0.11% of shares | medium |
| Mar 12, 2026 | Vivaldi Coelho Rogerio Director | Sell | Common Stock | $161.5K | -4K -21.02% | 16,823 0.02% of shares | medium |
| Mar 16, 2026 | Betz Stephen F. Executive | Sell | Common Stock | $160.2K | -4K -3.00% | 137,101 0.13% of shares | medium |
| Mar 16, 2026 | Knight Jeff E. Executive | Sell | Common Stock | $149.6K | -4K -3.42% | 112,018 0.11% of shares | medium |
| Jan 5, 2026 | Kalofonos Isabel Executive | Sell | Common Stock | $137.5K | -3K -74.98% | 834 <0.01% of shares | medium |
| Mar 3, 2026 | Okey Stephanie Director | Sell | Common Stock | $119.0K | -3K -18.40% | 13,300 0.01% of shares | medium |
| Jan 5, 2026 | Kalofonos Isabel Executive | Exercise | Common Stock | $101.5K | +3K +299.76% | 3,334 <0.01% of shares | low |
| Mar 12, 2026 | Vivaldi Coelho Rogerio Director | Sell | Common Stock | $19.2K | -523 -3.11% | 16,300 0.02% of shares | low |
| Jun 18, 2026 | Fust Matthew K Director | Grant | Common Stock | $0 | +6K +25.95% | 28,761 0.03% of shares | low |
| Jun 18, 2026 | Bedrosian Camille L Director | Grant | Common Stock | $0 | +6K +36.35% | 22,225 0.02% of shares | low |
| Jun 18, 2026 | Wierenga Wendell Director | Grant | Common Stock | $0 | +6K +5.10% | 122,071 0.12% of shares | low |
| Feb 23, 2026 | Struthers Richard Scott CEO | Grant | Common Stock | $0 | +62K +17.00% | 426,759 0.40% of shares | low |
| Feb 23, 2026 | Schilke Tobin Executive | Grant | Common Stock | $0 | +32K +60.57% | 84,834 0.08% of shares | low |
| Feb 23, 2026 | Knight Jeff E. Executive | Grant | Common Stock | $0 | +34K +38.67% | 121,929 0.11% of shares | low |
| Feb 23, 2026 | Betz Stephen F. Executive | Grant | Common Stock | $0 | +30K +25.49% | 147,713 0.14% of shares | low |
| Feb 23, 2026 | Kalofonos Isabel Executive | Grant | Common Stock | $0 | +34K +4076.74% | 34,834 0.03% of shares | low |
| Jun 18, 2026 | Fust Matthew K Director | Grant | Stock Option (Right to Buy) | — | +10K | 9,730 <0.01% of shares | low |
| Jun 18, 2026 | Bedrosian Camille L Director | Grant | Stock Option (Right to Buy) | — | +10K | 9,730 <0.01% of shares | low |
| Jun 18, 2026 | Wierenga Wendell Director | Grant | Stock Option (Right to Buy) | — | +10K | 9,730 <0.01% of shares | low |
| Feb 23, 2026 | Struthers Richard Scott CEO | Grant | Stock Option (Right to Buy) | — | +228K | 228,000 0.21% of shares | low |
| Feb 23, 2026 | Schilke Tobin Executive | Grant | Stock Option (Right to Buy) | — | +50K | 50,000 0.05% of shares | low |
| Feb 23, 2026 | Knight Jeff E. Executive | Grant | Stock Option (Right to Buy) | — | +55K | 55,000 0.05% of shares | low |
| Feb 23, 2026 | Betz Stephen F. Executive | Grant | Stock Option (Right to Buy) | — | +47K | 47,000 0.04% of shares | low |
| Feb 23, 2026 | Kalofonos Isabel Executive | Grant | Stock Option (Right to Buy) | — | +55K | 55,000 0.05% of shares | low |
| Jan 5, 2026 | Kalofonos Isabel Executive | Exercise | Stock Option (Right to Buy) | — | -3K -2.50% | 97,500 0.09% of shares | low |